1e
In Memoriam
16
19
1
49
2
2
18
1b
1d
18
33
2b
7
5f
1d
2 29
1d
25
Joel S. Bennett, M.D.
78
2b
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
4d
4
3
3
1d
4d
Division of Hematology-Oncology
16 814 BRB II/III
3b 421 Curie Boulevard/6160
Philadelphia, PA 19104
26
16 814 BRB II/III
3b 421 Curie Boulevard/6160
Philadelphia, PA 19104
30
Office: (215) 573-3280
35 Fax: (215) 573-7039
24
97
35 Fax: (215) 573-7039
24
Email:
BENNETTS@MAIL.MED.UPENN.EDU
12
BENNETTS@MAIL.MED.UPENN.EDU
18
Publications
23 a
3
2
29
4
b
1f
23 a
13
Education:
21 9 B.S. 14 (Pre-med) c
30 University of Michigan , 1963.
21 9 M.D. 20 (Medicine (Cum laude) c
2f University of Michigan, 1967.
c
3
3
3
3
8a
Permanent link21 9 B.S. 14 (Pre-med) c
30 University of Michigan , 1963.
21 9 M.D. 20 (Medicine (Cum laude) c
2f University of Michigan, 1967.
c
2 29
21
1e
1d
24
5e
65
1a 29
27
Description of Research Expertise
2ff Integrin function is essential for normal platelet adhesion and aggregation and participates i n the formation of the arterial thrombi that are responsible for heart attacks and strokes. The activation state of platelet integrins is regulated by platelet agonists, but the structural basis for this regulation is not known. Our studies indicate that helix-helix interactions involving the transmembrane and membrane-proximal cytoplasmic domain segments play an essential role in regulating the function of both beta 1 and beta 3 integrins. The current focus of the laboratory is to use biophysical and molecular biologic techniques to characterize these interactions in detail and to use this information to design potential anti-thrombotic agents.65
Description of Clinical Expertise
51 General Hematology, Internal Medicine, Hemostasis, and Thrombosis1a 29
23
147 Tan, S.K., Fong, K.P., Polizzi, N.F., Sternisha, A., Slusky, J.S.G., Yoon, K., DeGrado, W.F., and Bennett, J.S.: Modulating integrin aIIbb3 activity through mutagenesis of allosterically regulated inter-subunit contacts. Biochemistry 58: 3251-3259, 2019.
176 Mravic, M., Hu, H., Lu, Z., Bennett, J.S., Sanders, C.R., Orr, A.W., and DeGrado, W.F.: De novo designed transmembrane peptides activating the 51 integrin. Protein : De novo designed transmembrane peptides activating the 51 integrin. Protein Engineering, Design & Selection. 2018.
12a Kononova, O., Litvinov, R.I., Blokhin, D.S., Klochkov, V.V., Weisel, J.W., Bennett, J.S., Barsegov, V.: Mechanistic basis for the binding of RGD- and AGDV-peptides to the platelet integrin IIb3. Biochemistery 56, 2017.
d4 Bennett, J.S.: Are anti-platelet agents beneficial in Essential Thrombocythemia? Maybe yes, probably no. Ann. Int. Med. 167: 206-207, 2017.
a5 Bennett, J.S.: Clinical dilemma: Experts make the call. ASH Clinical News. 3(05): 34, 2017.
12d Bennett, J.S. : IIb3 (GPIIb/IIIa) structure and function. Platelets in Thrombotic and Non-Thrombotic Disorders. Gresele, P., Lopez, J.A., Kleiman, N.S., and Page, C.P., eds.) (eds.). Springer, Switzerland, 2: 99-109, 2017.
129 Höök, P., Litvinov, R.I., Kim, O.V., Xu, S., Bennett, J.S., Alber, M.S., and Weisel, J.W: Strong binding of platelet integrin IIb3 to fibrin clots: Potential target to destabilize thrombi. Scientific Reports 7, 2017.
150 Huntington, S.F., O’Hara, M.O., and Bennett, J.S: Platelet disorders: clinical and laboratory evaluation. Non-Malignant Hematology: Expert Clinical Perspective Ragni, M., Connors, J.M., and Abutalib, S., eds. (eds.). Springer, Switzerland, Page: 171-184, 2016.
132 Fong, F.P., Zhu, H., Span, L.M., Moore, D.T., Yoon, K., Tamura, R., Yin, H.H., DeGrado, W.F., and Bennett, J.S.: Directly activating IIb3 initiates outside-in signaling by causing IIb3 clustering. J. Bio. Chem/ 291, 2016.
2c
7
1d
1f
Selected Publications
137 Litvinov, R.I., Mravic, M., Zhu, H., Weisel, J.W., DeGrado, W.F., and Bennett, J.S.: Unique transmembrane domain interactions differentially modulate integrin avb3 and aIIbb3 function. Proc. Natl. Acad. Sci. U.S.A. 116: 11195-12300, 2019.147 Tan, S.K., Fong, K.P., Polizzi, N.F., Sternisha, A., Slusky, J.S.G., Yoon, K., DeGrado, W.F., and Bennett, J.S.: Modulating integrin aIIbb3 activity through mutagenesis of allosterically regulated inter-subunit contacts. Biochemistry 58: 3251-3259, 2019.
176 Mravic, M., Hu, H., Lu, Z., Bennett, J.S., Sanders, C.R., Orr, A.W., and DeGrado, W.F.: De novo designed transmembrane peptides activating the 51 integrin. Protein : De novo designed transmembrane peptides activating the 51 integrin. Protein Engineering, Design & Selection. 2018.
12a Kononova, O., Litvinov, R.I., Blokhin, D.S., Klochkov, V.V., Weisel, J.W., Bennett, J.S., Barsegov, V.: Mechanistic basis for the binding of RGD- and AGDV-peptides to the platelet integrin IIb3. Biochemistery 56, 2017.
d4 Bennett, J.S.: Are anti-platelet agents beneficial in Essential Thrombocythemia? Maybe yes, probably no. Ann. Int. Med. 167: 206-207, 2017.
a5 Bennett, J.S.: Clinical dilemma: Experts make the call. ASH Clinical News. 3(05): 34, 2017.
12d Bennett, J.S. : IIb3 (GPIIb/IIIa) structure and function. Platelets in Thrombotic and Non-Thrombotic Disorders. Gresele, P., Lopez, J.A., Kleiman, N.S., and Page, C.P., eds.) (eds.). Springer, Switzerland, 2: 99-109, 2017.
129 Höök, P., Litvinov, R.I., Kim, O.V., Xu, S., Bennett, J.S., Alber, M.S., and Weisel, J.W: Strong binding of platelet integrin IIb3 to fibrin clots: Potential target to destabilize thrombi. Scientific Reports 7, 2017.
150 Huntington, S.F., O’Hara, M.O., and Bennett, J.S: Platelet disorders: clinical and laboratory evaluation. Non-Malignant Hematology: Expert Clinical Perspective Ragni, M., Connors, J.M., and Abutalib, S., eds. (eds.). Springer, Switzerland, Page: 171-184, 2016.
132 Fong, F.P., Zhu, H., Span, L.M., Moore, D.T., Yoon, K., Tamura, R., Yin, H.H., DeGrado, W.F., and Bennett, J.S.: Directly activating IIb3 initiates outside-in signaling by causing IIb3 clustering. J. Bio. Chem/ 291, 2016.
2c